Experimental drug for lung sarcoidosis trial halted early

NCT ID NCT05314517

Terminated Disease control Sponsor: Kinevant Sciences GmbH Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 26 times

Summary

This study tested a drug called namilumab in 107 adults with chronic pulmonary sarcoidosis, a condition causing lung inflammation. The goal was to see if it could reduce the need for rescue treatments like steroids. The trial was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Kinevant Study Site

Birmingham, Alabama, 35233, United States
Kinevant Study Site

Palo Alto, California, 94304, United States
Kinevant Study Site

Valencia, California, 91355, United States
Kinevant Study Site

Denver, Colorado, 80206, United States
Kinevant Study Site

Gainesville, Florida, 32610, United States
Kinevant Study Site

Augusta, Georgia, 29841, United States
Kinevant Study Site

Chicago, Illinois, 60612, United States
Kinevant Study Site

Iowa City, Iowa, 52242, United States
Kinevant Study Site

Kansas City, Kansas, 66160, United States
Kinevant Study Site

New Orleans, Louisiana, 70115, United States
Kinevant Study Site

Baltimore, Maryland, 21234, United States
Kinevant Study Site

Minneapolis, Minnesota, 55414, United States
Kinevant Study Site

Rochester, Minnesota, 55905, United States
Kinevant Study Site

Greenville, North Carolina, 27834, United States
Kinevant Study Site

Cincinnati, Ohio, 45219, United States
Kinevant Study Site

Cleveland, Ohio, 44195, United States
Kinevant Study Site

Philadelphia, Pennsylvania, 19140, United States
Kinevant Study Site

Pittsburgh, Pennsylvania, 15213, United States
Kinevant Study Site

Charleston, South Carolina, 29425, United States
Kinevant Study Site

Rock Hill, South Carolina, 29732, United States
Kinevant Study Site

Dallas, Texas, 75390, United States
Kinevant Study Site

Houston, Texas, 77030, United States
Kinevant Study Site

Charlottesville, Virginia, 22908, United States
Kinevant Study Site

Falls Church, Virginia, 22042, United States
Kinevant Study Site

Brussels, 1200, Belgium
Kinevant Study Site

Leuven, 3000, Belgium
Kinevant Study Site

Liège, B-4000, Belgium
Kinevant Study Site

Yvoir, 5530, Belgium
Kinevant Study Site

Bobigny, 93000, France
Kinevant Study Site

Lille, 59037, France
Kinevant Study Site

Paris, 75018, France
Kinevant Study Site

Berlin, 14165, Germany
Kinevant Study Site

Essen, 45239, Germany
Kinevant Study Site

Freiburg im Breisgau, 79106, Germany
Kinevant Study Site

Hanover, 30625, Germany
Kinevant Study Site

Heidelberg, 69126, Germany
Kinevant Study Site

Leiden, 2333 ZA, Netherlands
Kinevant Study Site

Nieuwegein, 3435 CM, Netherlands
Kinevant Study Site

Rotterdam, 3015 GD, Netherlands
Kinevant Study Site

Ankara, 06620, Turkey (Türkiye)
Kinevant Study Site

Istanbul, 34134, Turkey (Türkiye)
Kinevant Study Site

Izmir, 35100, Turkey (Türkiye)
Kinevant Study Site

Izmir, 35330, Turkey (Türkiye)
Kinevant Study Site

Mersin, 33110, Turkey (Türkiye)
Kinevant Study Site

Cambridge, CB20QQ, United Kingdom
Kinevant Study Site

Cottingham, HU165JQ, United Kingdom
Kinevant Study Site

London, SE59RS, United Kingdom

Conditions

Explore the condition pages connected to this study.

SARCOIDOSIS, PULMONARY